Prodose Adaptive Aerosol Delivery system receives FDA approval
WEST SUSSEX, ENGLAND, April 28, 2004 -- Profile Therapeutics, announced that it has received regulatory approval from the FDA for its Prodose Adaptive Aerosol Delivery (AAD) system.
Prodose has already been launched in Europe to deliver Promixin, an inhaled antibiotic for treatment of patients with cystic fibrosis, and Ventavis, Schering AG's product for pulmonary hypertension. It has also been selected by CoTherix, Inc. for development of inhaled Iloprost for pulmonary hypertension.
Prodose is Profile's second generation AAD system. The third generation system, Prodose HandHeld, is in its final stages of development and planned to be available to patients for the first time later this year.
Source: Profile Therapeutics
Posted: April 2004